Английская Википедия:Amgen

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Third-party

Шаблон:Infobox company

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California.[1][2] One of the world's largest independent biotechnology companies, Amgen's Thousand Oaks staff in 2022 numbered approximately 5,000[3] (8.5% of total city employment)[4] and included hundreds of scientists, making Amgen the largest employer in Ventura County.[5][6] As of 2022, Amgen has approximately 24,000 staff in total.[7]

In 2019, the company's largest selling products were Enbrel (etanercept),[8] a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases, and Neulasta (pegfilgrastim), an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy.[9] Other marketed products include Evenity (romosozumab-aqqg), Otezla (apremilast), Prolia (denosumab), Repatha (evolocumab), and Lumakras (sotorasib).

History

Файл:AMGenelogo.jpg
AMGen corporate logo, 1983
Файл:Macri Amgen.jpg
Argentine president Mauricio Macri meets with heads of Amgen, in 2018.

Amgen was established in Thousand Oaks in 1980.[10][5] The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics, which became the official name of the company in 1983 (three years after incorporation and coincident with its initial public offering). The company's first chief executive officer, from 1980, was co-founder George B. Rathmann, followed by Gordon M. Binder in 1988,[11] followed by Kevin W. Sharer in 2000.[12] Robert A. Bradway became Amgen's president and chief executive officer in May 2012 following Sharer's retirement.[13] Amgen sponsored the Tour of California from 2011 to 2017.[14]

Timeline

  • 1980: Founded in Thousand Oaks, California, as Applied Molecular Genetics, Amgen was backed by a small group of venture capitalists. Its focus in early days was on recombinant DNA technology and recombinant human insulin.[15] William Bowes from Cetus Corporation recruits Winston Salser from UCLA to start Amgen with a scientific advisory board consisting of Norman Davidson, Leroy Hood, Arnold Berk, John Carbon, Robert Schimke, Arno Motulsky, Marvin H. Caruthers, and Dave Gibson.[16] In October, Amgen named George Rathmann its first president and chief executive officer.[15]
  • 1983: On June 17, Amgen went public, selling two million common shares and raising nearly $40 million.[17][18][19] That same year, after more than two years of work, an Amgen research team led by Fu-Kuen Lin had a breakthrough in finding and cloning the erythropoietin gene, a protein created in the kidney that stimulates red blood cell production. Lin's team created what would become Epogen (epoetin alfa).[20][21]
  • 1984: In June, Amgen and Kirin formed a joint venture giving Kirin the rights to Epogen in Japan.[22]
  • 1985: Amgen researcher Larry Souza and his team cloned granulocyte colony-stimulating factor (G-CSF), leading to the development of Neupogen (filgrastim).[21][23][24]
  • 1988: In October, Gordon Binder was named CEO, succeeding George Rathmann.[25]
  • 1989: Amgen received approval for the first recombinant human erythropoetin product, Epogen (epoetin alfa).[26][27]
  • 1991: In February 1991, Amgen received FDA approval for Neupogen for the prevention of infections in patients whose immune systems are suppressed due to cancer chemotherapy.[28] A 2002 meta-analysis found that Neupogen treatment reduced the risk of febrile neutropenia by 38%, reduced the risk of documented infection by 49%, and reduced the risk of infection-related mortality by 40%.[29]
  • 1993: In March, Amgen opened a new manufacturing facility in Puerto Rico, which later became the company's flagship manufacturing site.[30]
  • 1994: Amgen became the fifth company to receive the U.S. Department of Commerce's National Medal of Technology and Innovation, in recognition of its work developing medicines to improve quality of life for kidney and cancer patients.[31] Also around this time, Amgen researcher Steve Elliott and his team added more sugar molecules to erythropoietin, causing it to remain in the body longer. This led to the development of Aranesp (darbepoetin alfa).[32]
  • 1998: In November 1998, Immunex, a future acquisition of Amgen, received approval for Enbrel (etanercept), the first rheumatoid arthritis drug targeting tumor necrosis factor alpha (TNF-alpha).[26] A 2006 assessment by the National Institute of Clinical Excellence of the United Kingdom concluded that etanercept and related rheumatoid arthritis drugs later introduced by competitors "are effective treatments compared with placebo for RA patients who are not well controlled by conventional DMARDs, improving control of symptoms, improving physical function, and slowing radiographic changes in joints."[33] A more recent study demonstrated that compared to traditional disease-modifying anti-rheumatic drugs, treatment with etanercept improved survival, reduced cardiovascular events and reduced the incidence of hematological cancers.[34]
  • 2000: In May, Kevin Sharer became Amgen's third CEO, following Gordon Binder's retirement.[35]
  • 2001: Aranesp received FDA approval in September.[36]
  • 2002: At the beginning of the year, the FDA approved Neulasta.[37] In July, Amgen acquired Immunex, the developer of Enbrel (etanercept).[38]
  • 2004: Sensipar (cinacalcet) was approved by the FDA.[39][40] Also, Amgen acquired Tularik, another biotechnology company, expanding the company's research and development pipeline.[41][42]
  • 2006: In April, Amgen acquired Abgenix, the developer of Vectibix (panitumumab), a treatment developed for certain patients with metastatic colorectal cancer.[43] Vectibix was approved by the FDA in September 2006.[44]
  • 2008: In August, Nplate (romiplostim) was approved by the FDA.[45][46]
  • 2010: On June 6, 2010, Amgen received FDA approval for Prolia, a protein drug for the treatment of post-menopausal osteoporosis.[47] In clinical trials, Prolia reduced the rate of vertebral fractures by 61% and the risk of hip fractures by 40%.[48] In November 2010 the FDA approved Xgeva for the prevention of complications of bone metastases in patients with solid tumors.[49] The clinical trials primarily enrolled patients with breast or prostate cancer.
  • 2011: Amgen acquired a manufacturing facility near Dublin, Ireland, in March.[50] In May, Amgen acquired BioVex,[51] developer of Imlygic (talimogene laherparepvec).[52] In December, Amgen and Watson Pharmaceuticals announced a collaboration to develop and commercialize several biosimilar medicines worldwide.[53]
  • 2012: Illegal marketing practices. The Los Angeles Times reported on December 18, 2012, that Amgen pleaded guilty and agreed to pay $150 million in criminal penalty and $612 million to resolve 11 related whistleblower complaints. Federal prosecutors accused the company of pursuing profits while putting patients at risk.[54] Larry Husten, a contributor at Forbes.com elaborates on AMGEN's illegal marketing practices in this case, namely that the "government accused Amgen of marketing Aranesp for indications not approved by the FDA and other illegal marketing practices".[55] One of the drugs mentioned in the lawsuit had sales of $492 million in the third quarter of 2012, down 17% from the same quarter the previous year due to "reimbursement problems and label changes".[56]
  • 2013: Lawmakers inserted text into the fiscal cliff bill that will allow the drugmaker to sell a class of drugs that includes Sensipar without government controls for an additional two years. The New York Times estimated that the paragraph in the fiscal cliff bill will cost taxpayers an estimated $500 million[57] but other assessments concluded that the change would protect seniors in rural areas and reduce overall Medicare spending.[58][59] Amgen acquired Micromet, a company focused on BiTE technology, in March.[60] In May, Kevin Sharer retired, and Robert Bradway, formerly Amgen's president and chief operating officer, became CEO.[61] In June, Amgen acquired Turkish company Mustafa Nevzat Pharmaceuticals, expanding Amgen's presence in Turkey and nearby areas.[62] In July, Amgen acquired KAI Pharmaceuticals, developer of Parsabiv (etelcalcetide).[63][64] Amgen acquired Iceland-based deCODE Genetics in December.[65] Amgen also opened an affiliate in China.[66][67]
  • 2013: In October, Amgen acquired Onyx Pharmaceuticals, developer of Kyprolis (carfilzomib).[68]
  • 2014: In November the company announced it was halting all trials of rilotumumab in advanced gastric cancer patients after one of the trials found more deaths in those who took the compound with chemotherapy, than those without.[69] Later in the same week, the company in conjunction with AstraZeneca reported positive results for brodalumab in a Phase III trial comparing the compound with ustekinumab and a placebo in treating psoriasis.[70]
  • 2014: In November, construction was completed on Amgen's next-generation biomanufacturing facility in Singapore.[71] Blincyto (blinatumomab) was approved by the FDA in December.[72][73]
  • 2015: In March, the company announced it would license its Phase II candidate drug AMG 714 to developer Celimmune who plan to develop the anti-IL-15 monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease.[74]
  • 2015: Repatha (evolocumab) was approved by the FDA in August.[75] In September the company announced it would acquire Dezima Pharma for more than $1.55 billion.[76] The same day the company announced a collaboration with Xencor on 6 early stage immuno-oncology and inflammation programmes. As part of the deal Amgen will pay $45 million upfront, with the deal being worth up to another $1.7 billion.[77][78] In October, the FDA approved Imlygic.[79]
  • 2016: In September, the company announced it would purchase the rights to Boehringer Ingelheims Phase I bispecific T-cell engager compound (BI 836909, now AMG 420) for use in the treatment of multiple myeloma.[80] Also in September, the FDA approved Amjevita (adalimumab-atto).[81]
  • 2017: Cash returned to shareholders totalled a record $6.5 billion through dividends and share repurchases.[82] The FDA approved Parsabiv in February[83] and Mvasi (bevacizumab-awwb) in September.[84] In October, the Amgen Foundation pledged $3 million to Khan Academy to support the development of free online biology lessons.[85][86]
  • 2018: Amgen was ranked 123 on the Fortune 500 list of the largest United States corporations by revenue.[87] In May, Aimovig (erenumab-aooe) was approved by the FDA.[88] Amgen began constructing a next-generation biomanufacturing plant at its West Greenwich, Rhode Island, campus in July.[89]
  • 2019: In January, Evenity (romosozumab) received approval in Japan,[90][91] followed by FDA approval in April.[92] In June, Kanjinti (trastuzumab-anns) was approved by the FDA.[93] Amgen announced it would acquire Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million) to enhance its drug discovery capabilities.[94] In August the company announced it would acquire the Otezla drug programme from Celgene for $13.4 billion, as part of Celgene and Bristol-Myers Squibbs merger deal.[95][96] In October, Amgen announced it would be acquiring a 20.5% stake in the Beijing-based BeiGene for $2.7 billion.[97] In November, Amgen awarded a $2 million grant to the CDC Foundation to launch the latter's EmPOWERED Health Program, promoting patient engagement in decision making for their cancer treatment.[98] In December, the FDA approved Avsola (infliximab-axxq).[99]
  • 2020: In January, the Amgen Foundation and Harvard University debuted LabXchange, a free online science education platform.[100][101] Amgen and the Amgen Foundation announced a commitment of up to $12.5 million to support COVID-19 relief efforts in March.[102] In April, Amgen established Amgen K.K. as the company's wholly-owned affiliate in Japan.[103][104] Amgen announced in July that the United States Court of Appeals for the Federal Circuit had upheld the validity of two Amgen patents that described and claimed Enbrel and methods for making it. The appellate court affirmed an August 2019 decision by the United States District Court for the District of New Jersey and rejected Sandoz's attempt to invalidate the patents on Enbrel.[105] Also in July, Amgen granted an additional $3 million Khan Academy to support educational equity and science learning.[106][107] Amgen joined the Dow Jones Industrial Average on August 24, 2020.[108] In September, Amgen and Eli Lilly and Company announced a global manufacturing collaboration for COVID-19 antibody therapies.[109] On December 10, Amgen announced that it joined OneTen, a coalition of large employers that aims to hire and advance one million black Americans over the next ten years.[110] Later that month, the FDA approved Riabni (rituximab-arrx), a biosimilar to Rituxan.[111]
  • 2021: In March, the company announced it would acquire Five Prime Therapeutics and its lead candidate, bemarituzumab, for $1.9 billion[112][113] and Rodeo Therapeutics for up to $720 million.[114] The FDA approved Amgen's Lumakras in May for treatment of patients with KRAS-G12C-mutated non-small cell lung cancer.[115] In June, Amgen and Kyowa Kirin announced joint plans to develop and commercialize a treatment for atopic dermatitis.[116] In July, Amgen acquired Teneobio for $900 million. In October, Amgen and Neumora Therapeutics announced a research and development collaboration focused on novel precision therapies for certain brain diseases.[117][118] Amgen began construction on a new biomanufacturing plant in New Albany, Ohio, in November.[119] In December, the FDA approved Amgen and AstraZeneca's Tezspire (tezepelumab) for severe asthma.[120] The FDA also approved Amgen's Otezla for adults with plaque psoriasis of any severity level.[121]
  • 2022: In January, Amgen announced a research collaboration with Generate Biomedicines across multiple modalities and several therapeutic areas for up to $1.9 billion.[122][123] The company also launched a multi-target collaboration with Arrakis Therapeutics to identify novel targeted RNA degrader therapeutics.[124][125] The next month, Amgen entered a multi-year collaboration with Plexium to discover novel targeted protein degradation therapies.[126][127] Also in February, Amgen issued its first green bond to fund various environmentally friendly initiatives across the company.[128][129] The company broke ground on a new manufacturing facility in Holly Springs, North Carolina, in March.[130][131] In August, the company agreed to acquire ChemoCentryx for $3.7 billion in an all-cash deal. ChemoCentryx is the maker of Tavneos—a drug treatment for rare diseases called anti-neutrophil cytoplasmic autoantibody-associated vasculitis—which was approved last year.[132] In December, the company announced it would acquire Horizon Therapeutics for $27.8 billion ($116.50 in cash for each Horizon share, a 20% premium) expanding its rare disease treatments.[133]
  • 2023: Amgen completed the acquisition of Horizon Therapeutics in October 2023.[134] In December, announced plans to use artificial intelligence in partnership with Amazon Web Services to help discover and create medicines.[135] Amgen will use Amazon's SageMaker machine learning service to help with the manufacturing process.[135]

Acquisition history

Шаблон:Hidden start Шаблон:Tree list

  • Amgen (Founded 1983 as Applied Molecular Genetics)
    • Synergen Inc (Acq 1994)
    • Kinetix Pharmaceuticals Inc (Acq 2000)
    • Immunex Corporation (Acq 2002)
    • Tularik Inc (Acq 2004)
    • Abgenix Inc (Acq 2006)
    • Avidia Inc (Acq 2006)
    • Alantos Pharmaceuticals (Acq 2007)
    • Ilypsa Inc (Acq 2007)
    • BioVex Group Inc (Acq 2011)
    • Micromet Inc (Acq 2012)
    • Mustafa Nevzat İlaç (Acq 2012)
    • KAI Pharmaceuticals (Acq 2012)
    • deCODE genetics (Acq 2012)
    • Onyx Pharmaceuticals (Acq 2013)
    • NextCODE genetics (Spun off 2013)
    • Dezima Pharma (Acq 2015)
    • Catherex (Acq 2015)
    • Nuevolution AB (Acq 2019)
    • Otezla (apremilast) (Acq 2019)[136]
    • Five Prime Therapeutics (Acq 2021)[137]
    • Rodeo Therapeutics Corporation (Acq 2021)[138]
    • Teneobio (Acq 2021)
    • ChemoCentryx (Acq 2022)[139]
    • Horizon Therapeutics (Acq 2023)
      • Vidara Therapeutics International (Acq 2014)
      • Hyperion Therapeutics (Acq 2015)
      • Crealta Holdings (Acq 2015)
      • Raptor Pharmaceutical (Acq 2016)
      • River Vision Development Corp. (Acq 2017)
      • Viela Bio Inc (Acq 2021)

Шаблон:Tree list/end Шаблон:Hidden end

Products

Amgen's approved drugs or therapeutic biologicals include:

Products developed and then sold off

Pipeline and clinical trials

As of August 2022, Amgen had 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I.[144]

In September 2019, FDA granted fast track designation to sotorasib for the treatment of metastatic non-small-cell lung carcinoma (NSCLC) with the KRAS G12C mutation.[145]

In August 2020, Amgen, Takeda, and AbbVie, as part of a COVID-19 research and development (R&D) alliance, announced the first patients enrolled in the I-SPY COVID clinical trial. The trial evaluated the efficacy of Otezla and two other medicines in severely ill, hospitalized COVID-19 patients who required high-flow oxygen.[146]

In October 2020, Amgen announced positive topline Phase 2 results from the CodeBreaK 100 clinical study, evaluating sotorasib in 126 patients with KRAS G12C-mutant advanced NSCLC who had failed three or fewer prior lines of anti-cancer therapies (including immunotherapy and/or chemotherapy).[147] Amgen, the Global Coalition for Adaptive Research, and Eisai Co., Ltd. also announced enrollment of the first patient in a study testing multiple interventions for the treatment of patients hospitalized with COVID-19.[148][149]

In November 2020, Amgen, Takeda, and UCB, as part of the COVID R&D alliance, announced the first patient enrolled in another trial evaluating Otezla and two other drugs as treatments for COVID-19.[150] Amgen also announced that it would terminate its collaboration with Cytokinetics and transition the development and commercialization rights for omecamtiv mecarbil and AMG 594.[151] Amgen and AstraZeneca announced positive topline results from a Phase 3 trial in which the investigational medicine tezepelumab demonstrated a statistically significant reduction in exacerbations in patients with severe asthma.[152]

In December 2020, the FDA granted breakthrough therapy designation to sotorasib for advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation.[153]

In May 2021, sotorasib received accelerated approval from FDA for treatment of adult patients with NSCLC whose tumors have a KRAS G12C mutation and who have received at least one prior systemic therapy; this was the first approved targeted therapy for tumors with any KRAS mutation.[154] Similar approvals for sotorasib in NSCLC followed in January 2022 in Europe[155] and Japan.[156]

In September 2022, data from a late-stage study showed the company's cancer pill Lumakras beating out chemotherapy. This was the first approved drug in the set of treatments that target KRAS, among the most common generic mutations found in cancers but one where researchers have struggled for years to design drugs to treat. The drug was approved in 2021 with a list price of $17,900 per month.[157]

Carbon footprint

Amgen reported Total CO2e emissions (Direct + Indirect) for the twelve months ending 31 December 2020 at 243 Kt (-6 /-2.4% y-o-y)[158] and aims to reach net zero emissions by 2027.[159]

Amgen's annual Total CO2e Emissions - Location-Based Scope 1 + Scope 2 (in kilotonnes)[158]
Dec 2014 Dec 2015 Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020
354 369 292 279 264 249 243

Public-private engagement

Amgen engages with the public and private sectors in a variety of settings including to promote research and development, academic funding, event sponsorship, philanthropy, and political lobbying.

Academia

Events and conferences

Health care

Media

Medical societies

Political lobbying

Professional associations

Research and development

See also

Шаблон:Portal

References

Шаблон:Reflist

External links

Шаблон:Commons category

Шаблон:Finance links

Шаблон:Pharmaceutical companies of the United States Шаблон:Dow Jones Industrial Average companies Шаблон:NASDAQ-100 Шаблон:Authority control

Партнерские ресурсы
Криптовалюты
Магазины
Хостинг
Разное

  1. ↑ Amgen History official site page accessed January 2, 2016
  2. ↑ Ronald Vogel. Pharmaceutical Economics and Public Policy. CRC Press, 2007. Шаблон:ISBN. P. 208
  3. ↑ Шаблон:Cite news
  4. ↑ Шаблон:Cite news
  5. ↑ 5,0 5,1 Baker, Pam (2002). Thousand Oaks Westlake Village: A Contemporary Portrait. Community Communications, Inc., p. 37. Шаблон:ISBN.
  6. ↑ Шаблон:Cite web
  7. ↑ Шаблон:Cite news
  8. ↑ Шаблон:Cite news
  9. ↑ Шаблон:Cite news
  10. ↑ Bidwell, Carol A. (1989). The Conejo Valley: Old and New Frontiers. Windsor Publications. p. 128. Шаблон:ISBN.
  11. ↑ Шаблон:Cite web
  12. ↑ Шаблон:Cite web
  13. ↑ Шаблон:Cite web
  14. ↑ Шаблон:Cite web
  15. ↑ 15,0 15,1 Шаблон:Cite web
  16. ↑ Шаблон:Cite web
  17. ↑ Шаблон:Cite web
  18. ↑ Шаблон:Cite web
  19. ↑ Шаблон:Cite web
  20. ↑ Шаблон:Cite web
  21. ↑ 21,0 21,1 Шаблон:Cite book
  22. ↑ Шаблон:Cite news
  23. ↑ Шаблон:Cite news
  24. ↑ Шаблон:Cite journal
  25. ↑ Шаблон:Cite news
  26. ↑ 26,0 26,1 Шаблон:Cite web
  27. ↑ Шаблон:Cite news
  28. ↑ Шаблон:Cite web
  29. ↑ Шаблон:Cite journal
  30. ↑ Шаблон:Cite news
  31. ↑ Шаблон:Cite news
  32. ↑ Шаблон:Cite news
  33. ↑ Шаблон:Cite journal
  34. ↑ Шаблон:Cite journal
  35. ↑ Шаблон:Cite news
  36. ↑ Шаблон:Cite news
  37. ↑ Шаблон:Cite news
  38. ↑ Шаблон:Cite news
  39. ↑ Шаблон:Cite web
  40. ↑ Шаблон:Cite web
  41. ↑ Шаблон:Cite news
  42. ↑ Шаблон:Cite web
  43. ↑ Шаблон:Cite news
  44. ↑ Шаблон:Cite journal
  45. ↑ Шаблон:Cite news
  46. ↑ Шаблон:Cite journal
  47. ↑ Шаблон:Cite web
  48. ↑ Шаблон:Cite web
  49. ↑ Шаблон:Cite web
  50. ↑ Шаблон:Cite news
  51. ↑ Шаблон:Cite news
  52. ↑ Шаблон:Cite news
  53. ↑ Шаблон:Cite news
  54. ↑ Шаблон:Cite news
  55. ↑ Шаблон:Cite news
  56. ↑ Шаблон:Cite web
  57. ↑ Шаблон:Cite news
  58. ↑ Шаблон:Cite news
  59. ↑ Шаблон:Cite web
  60. ↑ Шаблон:Cite news
  61. ↑ Шаблон:Cite news
  62. ↑ Шаблон:Cite news
  63. ↑ Шаблон:Cite news
  64. ↑ Шаблон:Cite news
  65. ↑ Шаблон:Cite news
  66. ↑ Шаблон:Cite news
  67. ↑ Шаблон:Cite news
  68. ↑ Шаблон:Cite news
  69. ↑ Шаблон:Cite web
  70. ↑ Шаблон:Cite web
  71. ↑ Шаблон:Cite news
  72. ↑ Шаблон:Cite journal
  73. ↑ Шаблон:Cite news
  74. ↑ Шаблон:Cite web
  75. ↑ Шаблон:Cite news
  76. ↑ Шаблон:Cite web
  77. ↑ Шаблон:Cite news
  78. ↑ Шаблон:Cite web
  79. ↑ Шаблон:Cite web
  80. ↑ Шаблон:Cite web
  81. ↑ 81,0 81,1 Шаблон:Cite news
  82. ↑ Шаблон:Cite web
  83. ↑ Шаблон:Cite news
  84. ↑ 84,0 84,1 Шаблон:Cite web
  85. ↑ Шаблон:Cite news
  86. ↑ Шаблон:Cite news
  87. ↑ Шаблон:Cite web
  88. ↑ Шаблон:Cite journal
  89. ↑ Шаблон:Cite web
  90. ↑ Шаблон:Cite web
  91. ↑ Шаблон:Cite news
  92. ↑ Шаблон:Cite news
  93. ↑ 93,0 93,1 Шаблон:Cite web
  94. ↑ Шаблон:Cite news
  95. ↑ Шаблон:Cite web
  96. ↑ Шаблон:Cite news
  97. ↑ Шаблон:Cite web
  98. ↑ Шаблон:Cite web
  99. ↑ Шаблон:Cite news
  100. ↑ Шаблон:Cite news
  101. ↑ Шаблон:Cite news
  102. ↑ Шаблон:Cite news
  103. ↑ Шаблон:Cite news
  104. ↑ Шаблон:Cite news
  105. ↑ Шаблон:Cite news
  106. ↑ Шаблон:Cite news
  107. ↑ Шаблон:Cite news
  108. ↑ Шаблон:Cite news
  109. ↑ Шаблон:Cite news
  110. ↑ Шаблон:Cite news
  111. ↑ 111,0 111,1 Шаблон:Cite news
  112. ↑ Шаблон:Cite web
  113. ↑ Шаблон:Cite news
  114. ↑ Шаблон:Cite web
  115. ↑ 115,0 115,1 Шаблон:Cite news
  116. ↑ Шаблон:Cite news
  117. ↑ Шаблон:Cite news
  118. ↑ Шаблон:Cite news
  119. ↑ Шаблон:Cite news
  120. ↑ 120,0 120,1 Шаблон:Cite news
  121. ↑ Шаблон:Cite news
  122. ↑ Шаблон:Cite news
  123. ↑ Шаблон:Cite news
  124. ↑ Шаблон:Cite news
  125. ↑ Шаблон:Cite news
  126. ↑ Шаблон:Cite news
  127. ↑ Шаблон:Cite news
  128. ↑ Шаблон:Cite news
  129. ↑ Шаблон:Cite news
  130. ↑ Шаблон:Cite web
  131. ↑ Шаблон:Cite news
  132. ↑ Шаблон:Cite news
  133. ↑ Шаблон:Cite news
  134. ↑ Шаблон:Cite news
  135. ↑ 135,0 135,1 Шаблон:Cite web
  136. ↑ Шаблон:Cite news
  137. ↑ Шаблон:Cite news
  138. ↑ Шаблон:Cite news
  139. ↑ Шаблон:Cite news
  140. ↑ Food and Drug Administration December 3, 2014 FDA Press release: Blinatumomab
  141. ↑ Шаблон:Cite news
  142. ↑ 142,0 142,1 142,2 Amgen press office. Biovitrum Closes Product Acquisition Deal with Amgen Шаблон:Webarchive
  143. ↑ Шаблон:Cite web
  144. ↑ Шаблон:Cite web
  145. ↑ Шаблон:Cite news
  146. ↑ Шаблон:Cite news
  147. ↑ Шаблон:Cite news
  148. ↑ Шаблон:Cite news
  149. ↑ Шаблон:Cite news
  150. ↑ Шаблон:Cite news
  151. ↑ Шаблон:Cite news
  152. ↑ Шаблон:Cite news
  153. ↑ Шаблон:Cite news
  154. ↑ Шаблон:Cite news
  155. ↑ Шаблон:Cite news
  156. ↑ Шаблон:Cite news
  157. ↑ Шаблон:Cite news
  158. ↑ 158,0 158,1 Шаблон:Cite web Alt URL
  159. ↑ Шаблон:Cite web Alt URL
  160. ↑ Шаблон:Cite web
  161. ↑ Шаблон:Cite web
  162. ↑ Шаблон:Cite web
  163. ↑ Шаблон:Cite web
  164. ↑ Шаблон:Cite web
  165. ↑ Шаблон:Cite web
  166. ↑ Шаблон:Cite web
  167. ↑ Шаблон:Cite web
  168. ↑ Шаблон:Cite web
  169. ↑ Шаблон:Cite web
  170. ↑ Шаблон:Cite web
  171. ↑ Шаблон:Cite web
  172. ↑ Шаблон:Cite web
  173. ↑ Шаблон:Cite web
  174. ↑ 174,0 174,1 Шаблон:Cite web
  175. ↑ Шаблон:Cite web
  176. ↑ Шаблон:Cite web
  177. ↑ Шаблон:Cite web
  178. ↑ Шаблон:Cite web
  179. ↑ Шаблон:Cite web
  180. ↑ Шаблон:Cite web
  181. ↑ Шаблон:Cite web
  182. ↑ Шаблон:Cite web
  183. ↑ Шаблон:Cite web
  184. ↑ Шаблон:Cite web
  185. ↑ Шаблон:Cite web
  186. ↑ Шаблон:Cite web
  187. ↑ Шаблон:Cite web
  188. ↑ Шаблон:Cite web
  189. ↑ Шаблон:Cite web
  190. ↑ Шаблон:Cite web
  191. ↑ Шаблон:Cite web
  192. ↑ Шаблон:Cite web
  193. ↑ Шаблон:Cite web
  194. ↑ Шаблон:Cite web
  195. ↑ Шаблон:Cite web
  196. ↑ Шаблон:Cite web
  197. ↑ Шаблон:Cite web
  198. ↑ Шаблон:Cite web
  199. ↑ Шаблон:Cite web
  200. ↑ Шаблон:Cite web
  201. ↑ Шаблон:Cite web
  202. ↑ Шаблон:Cite web
  203. ↑ Шаблон:Cite web
  204. ↑ Шаблон:Cite web
  205. ↑ Шаблон:Cite web
  206. ↑ Шаблон:Cite web
  207. ↑ Шаблон:Cite web
  208. ↑ Шаблон:Cite web
  209. ↑ Шаблон:Cite web
  210. ↑ Шаблон:Cite web
  211. ↑ Шаблон:Cite web
  212. ↑ Шаблон:Cite web
  213. ↑ Шаблон:Cite web
  214. ↑ Шаблон:Cite web
  215. ↑ Шаблон:Cite journal
  216. ↑ Шаблон:Cite web
  217. ↑ Шаблон:Cite web
Источник — http://wikihandbk.com/ruwiki/index.php?title=Английская_Википедия:Amgen&oldid=13112169